Signal #144095 · SEC 8-K

$RNAC SEC Filing Alert & Real-Time AI Stock Impact Analysis

Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).

FAQ: $RNAC filing catalyst

Why did $RNAC trigger an AI stock catalyst alert?

$RNAC triggered a Stock Catalyst AI alert on 2026-11-05 00:00:00 UTC for a SEC 8-K filing (AI Score: +0.5/10). Headline: Cartesian Therapeutics Reports Q3 Results; Cash Runway Extends Into 2028. Key points: - Operating loss of ~$25M with no commercial revenue, typical for development-stage biotech. - Cash and equivalents of $123M expected to fund operations into 2028. - Phase 3 AURORA trial readout targeted for 1Q27 with planned BLA filing in mid-2027.

How did $RNAC stock react after the SEC filing?

After the SEC 8-K for $RNAC, observed market reaction: T0 price $6.82. Past moves do not guarantee future results.

Where can I get real-time $RNAC SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $RNAC via Telegram and the VIP Web Terminal from €10/month.

$RNAC

$RNAC – Cartesian Therapeutics Reports Q3 Results; Cash Runway Extends Into 2028

Cartesian Therapeutics, Inc.

2026-11-05 00:00:00 UTC · SEC 8-K · All $RNAC

Unlocked archive · Analyzed in <2s at T0

Neutral AI Sentiment (+0.5 / 10)

Operating loss of ~$25M with no commercial revenue, typical for development-stage biotech.
Cash and equivalents of $123M expected to fund operations into 2028.
Phase 3 AURORA trial readout targeted for 1Q27 with planned BLA filing in mid-2027.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →